NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at Morgan Stanley from Equal-weight to Overweight. $60 price target. Relative valuation call, even though regulatory risks remain.
downgraded at Goldman from Neutral to Sell. Valuation call, based on a $213 price target.
rated new Overweight at Piper Jaffray. $30 price target. Company can exceed earnings expectations in the coming quarters, aided by merger synergies.
upgraded at Barclays. ERIC upgraded to Equal Weight from Underweight as many negative pressures should abate in 2H10 and 2011. Price target increased to $11 from $10.
upgraded at Barclays to Overweight from Equal Weight. Continued success in the Granite Wash & Nikanassin play could underpin strong production growth over next several years. Price target lifted from $38 to $40.
upgraded at Goldman from Sell to Neutral. $24 price target. Estimates also boosted, as used car sales are becoming more profitable.
upgraded at Barclays to Overweight from Equal Weight. Near term portfolio strengthening and potential long term strategic improvement from the CEO drives upgrade. Shares now seen reaching $13, up from $10.
downgraded at Citigroup from Buy to Hold. $14 price target. Valuation call, as the stock is up more than 10% over the past six months.
upgraded at Citigroup from Hold to Buy. $70 price target. Near-term trends are improving and Spotlight initiative should drive future growth.
downgraded at Credit Suisse to Neutral from Outperform. Last week's tragic gas pipeline explosion will create a wave of real and rhetorical political backlash for PCG. Price target fell to $45 from $50.
Public Service Enterprise
downgraded at Barclays from Overweight to Equal Weight based on lack of near term catalysts, reduced earnings. Price target cut by a dollar to $35.
upgraded at Barclays to Overweight from Equal Weight. Production issues they faced during the second quarter have mostly been resolved. Price target trimmed to $25 from $30.
Research in Motion
downgraded at Susquehanna to Negative. $37.50 price target. Checks indicate lower Touch sales and increased smartphone competition.
Research in Motion
estimates sink at Credit Suisse. RIMM 2011 and 2012 EPs estimates trimmed to $5.63 and $6.09, respectively. Pressure on RIMM's enterprise position. Reiterate Outperform rating.
Research in Motion
estimates reduced at Goldman through 2013. Competition is growing in the smartphone market. Sell rating.
downgraded at Baird from Outperform to Neutral. $27 price target. Checks show lower consumer PC demand.
upgraded at Wells from Market Perform to Outperform. Company can deliver above-average growth.
downgraded at Deutsche from Buy to Hold. $65 price target. Natural gas should be in fundamental oversupply for the next few years.
STOCK COMMENTS / EPS CHANGES
target, estimates lower at Credit Suisse. AMAT 2010 and 2011 EPS estimates set at $0.82 and $0.97, respectively. Price target dropped to $12.25 from $13.50. Lower industry capex spending. Reiterate Neutral rating.
target reduced at FBR. Shares of ATHR now seen reaching $35. Company is leveraged to lower PC demand. Outperform rating.
price target cut at Credit Suisse to $6 from $8.40 on weaker industry capex estimates. Maintain Neutral rating.
numbers raised at Morgan Stanley. Shares of CF now seen reaching $115. Estimates also increased, given higher corn and lower gas prices. Overweight rating.
added to Conviction Buy List at Goldman. CMI was added to the Conviction Buy list. Estimates also boosted, given accelerating new product sales. Buy rating and new $104 price target.
target increased at Kaufman to $140. New bookings growth is accelerating. Buy rating.
numbers higher at Barclays. ENTR 2010 and 2011 EPS estimates raised to 43 cents and 66 cents, respectively. Price target lifted to $12 from $9. Buoyant trends following recent industry checks. Maintain Overweight rating.
Health Management Associates
target trimmed at Barclays by a dollar to $10. Lower utilization may be significant headwind to hospital results in 2010. Maintain Overweight rating.
numbers cut at Deutsche Bank. Shares of LMT now seen reaching $82. Estimates also lowered, given another delay in the joint-strike fighter. Hold rating.
cut from Conviction Buy List at Goldman Sachs. Stock has outperformed and CMI offers better upside potential. $104 price target.
estimates, target cut at Goldman. Shares of NAV now seen reaching $49. Estimates also lowered, given weaker engine margins. Neutral rating.
price target trimmed at Credit Suisse to $35 from $39.90 on potential near-term weakness in upstream/midstream tech. Reiterate Outperform rating.
estimates, target reduced at Morgan Stanley. PCG estimates were lowered through 2012. Accident in California will hurt earnings, on top of the potential liability. Equal-weight rating and new $46 price target.
target boosted at FBR. Shares of RVBD now seen reaching $46. Checks show strong demand across the board. Outperform rating.
price target cut at Barclays to $6 from $10 on low gas prices. Maintain Overweight rating.
price target reduced at Barclays. THC price target fell to $6 from $8 on lower utilization rates in hospitals. Maintain Overweight rating.
This article was written by a staff member of TheStreet.